# Buprenorphine for Cancer Pain

> **NCT05910190** · PHASE4 · UNKNOWN · sponsor: **Fox Chase Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Cancer-Related Pain

## Interventions

- **DRUG:** Use of buprenorphine with FAO > 30 OME
- **BEHAVIORAL:** CPM Rx application use

## Key facts

- **NCT ID:** NCT05910190
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-10
- **Primary completion:** 2024-10-10
- **Final completion:** 2024-10-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910190, "Buprenorphine for Cancer Pain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05910190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*